LIVE

BMRN

BioMarin Pharmaceutical Inc.

BMRN

NASDAQ·Healthcare·Biotechnology·Mkt cap $11.2B

$58.64

▲ +1.41%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$49.26 - $66.28

P/E

41.88

Fwd P/E

14.04

Beta

0.24

Div Yield

0.00%

Avg Vol

2.1M

Shares Out

192.3M

Mkt Cap

$11.2B

Price action

Price chart

Up 1.1% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Specialized rare disease expertise
  • Robust clinical development pipeline
  • Proprietary genetic treatment technologies
  • Strong intellectual property portfolio
▼

Bear Case

1 risk

  • Low volatility (beta 0.2).

Growth

Stable outlook

Expanding rare disease treatment portfolio

Value

Undervalued - trading well below Biotech & Therapeutics peers

Momentum

Stable

+4.2% over 3m

Quality

Excellent

Excellent business quality

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Apr 29, 2026

“
Q2 26 RECAP

MAY 4, 2026

Reported EPS of $0.55 vs $0.94 consensus (-41.5% surprise). Revenue of $766.0M vs $752.2M expected (+1.8%).

EPS miss
Rev beat +1.8%

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-41.5%

Next: Apr 29, 2026

Revenue trend · last 8Q

—

—

+16%

+15%

+16%

+4%

+17%

+3%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$712.0M

$745.7M

$747.3M

$745.1M

$825.4M

$776.1M

$874.6M

$766.2M

Margins · last 8Q

Gross

—

Operating

—

Profit

13.8%

View full earnings history →

Wall Street consensus

13 analysts · 85% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

11

85%

Hold

2

15%

Sell

0%

Median Price Target

$82.00

▲ +39.8% vs $58.64

Low $50.00
Median $82.00
High $120.00

Latest: Canaccord · $111.00 · May 22, 2026

7 analysts covering

View full analyst page →

vs Industry

How BMRN stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.